Weijin Huang
A5076011780- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Hepatitis B Virus Studies
- Viral Infections and Outbreaks Research
- SARS-CoV-2 detection and testing
- Hepatitis Viruses Studies and Epidemiology
- Virus-based gene therapy research
- vaccines and immunoinformatics approaches
- Viral Infections and Vectors
- Respiratory viral infections research
- Liver Disease and Transplantation
- Hepatitis C virus research
- Cervical Cancer and HPV Research
- Influenza Virus Research Studies
- Bacillus and Francisella bacterial research
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- HIV Research and Treatment
- Herpesvirus Infections and Treatments
- Mosquito-borne diseases and control
- Virology and Viral Diseases
- HIV/AIDS drug development and treatment
- Bacteriophages and microbial interactions
National Institutes for Food and Drug Control
2016-2025
Yueyang Hospital
2025
Shanghai University of Traditional Chinese Medicine
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2022-2025
China Electronics Standardization Institute
2025
Peking Union Medical College Hospital
2025
Dalian University
2025
Jinan University
2024
Southern University of Science and Technology
2024
First Affiliated Hospital of Fujian Medical University
2024
The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation. Here we use high-throughput yeast display screening1,2 to determine profiles RBD escaping for 247 human anti-RBD and show that can be classified by unsupervised clustering into six epitope groups (A-F)-a grouping is highly concordant with knowledge-based structural classifications3-5. Various single...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.2.12.1, BA.4 and BA.5 exhibit higher transmissibility than the BA.2 lineage 1 . The receptor binding immune-evasion capability of these recently emerged variants require immediate investigation. Here, coupled with structural comparisons spike proteins, we show that (BA.4 are hereafter referred collectively to as BA.4/BA.5) similar affinities for angiotensin-converting enzyme (ACE2) receptor. Of note,...
Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging re-emerging viruses. Due to its high pathogenicity infectivity the lack effective vaccines therapeutics, live SARS-CoV-2 has be handled under biosafety level 3 conditions, which hindered development therapeutics. Based on a VSV pseudovirus production system, pseudovirus-based neutralization assay been developed evaluating neutralizing antibodies against in 2 facilities. The key...
To discover new drugs to combat COVID-19, an understanding of the molecular basis SARS-CoV-2 infection is urgently needed. Here, for first time, we report crucial role cathepsin L (CTSL) in patients with COVID-19. The circulating level CTSL was elevated after and positively correlated disease course severity. Correspondingly, pseudovirus increased expression human cells vitro ACE2 transgenic mice vivo, while overexpression, turn, enhanced cells. functionally cleaved spike protein virus...
As the emerging variants of SARS-CoV-2 continue to drive worldwide pandemic, there is a constant demand for vaccines that offer more effective and broad-spectrum protection. Here, we report circular RNA (circRNA) vaccine elicited potent neutralizing antibodies T cell responses by expressing trimeric RBD spike protein, providing robust protection against in both mice rhesus macaques. Notably, circRNA enabled higher durable antigen production than 1mΨ-modified mRNA proportion distinct...
A steric block to SARS-CoV-2 In response infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immune system makes antibodies, many of which target spike protein, a key player in host cell entry. Antibodies that potently neutralize virus hold promise as therapeutics and could inform vaccine design. Lv et al. report humanized monoclonal antibody protected against mouse model. The cryo–electron microscopy structure, together with biochemical, cellular, virological...
The 501Y.V2 variants of SARS-CoV-2 containing multiple mutations in spike are now dominant South Africa and rapidly spreading to other countries. Here, experiments with 18 pseudotyped viruses showed that the do not confer increased infectivity cell types except for murine ACE2-overexpressing cells, where a substantial increase was observed. Notably, susceptibility 12 17 neutralizing monoclonal antibodies substantially diminished, neutralization ability sera from convalescent patients...
The emergence of Omicron/BA.1 has brought new challenges to fight against SARS-CoV-2. A large number mutations in the Spike protein suggest that its susceptibility immune protection elicited by existing COVID-19 infection and vaccines may be altered. In this study, we constructed pseudotyped SARS-CoV-2 variant Omicron. sensitivity 28 serum samples from convalescent patients infected with original strain was tested Omicron as well other variants concern (VOCs, Alpha, Beta, Gamma, Delta)...
Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part transmission. An efficacious vaccine for adolescents could therefore assist pandemic control. For further evaluation of the inactivated COVID-19 candidate BBIBP-CorV, we assessed safety immunogenicity BBIBP-CorV participants aged 3-17 years.
Abstract Omicron (B.1.1.529), the most heavily mutated SARS-CoV-2 variant so far, is highly resistant to neutralizing antibodies, raising concerns about effectiveness of antibody therapies and vaccines 1,2 . Here we examined whether sera from individuals who received two or three doses inactivated vaccine could neutralize authentic Omicron. The seroconversion rates antibodies were 3.3% (2 out 60) 95% (57 for had 2 3 vaccine, respectively. For recipients doses, geometric mean neutralization...
Abstract SARS-CoV-2 is the underlying cause for COVID-19 pandemic. Like most enveloped RNA viruses, uses a homotrimeric surface antigen to gain entry into host cells. Here we describe S-Trimer, native-like trimeric subunit vaccine candidate based on Trimer-Tag technology. Immunization of S-Trimer with either AS03 (oil-in-water emulsion) or CpG 1018 (TLR9 agonist) plus alum adjuvants induced high-level neutralizing antibodies and Th1-biased cellular immune responses in animal models....
Abstract SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal (NTD). Here we report humoral response to circulating variants, such as 501Y.V2 (B.1.351), of plasma neutralizing antibodies (NAbs) elicited CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) natural infection. Among 86 potent NAbs identified high-throughput single-cell VDJ sequencing peripheral blood mononuclear cells from vaccinees convalescents, near half...
Abstract Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical interventions against COVID-19 disease. However, their common genetic and biologic features remain elusive. Here we interrogate a total of 165 from eight patients, find that potent nAbs different patients have disproportionally high representation IGHV3-53/3-66 usage, therefore termed as public antibodies. Crystal structural comparison these reveals they share similar angle approach RBD, overlap in...
The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important target for vaccine and drug development. However, the rapid emergence variant strains with mutated S proteins has rendered many treatments ineffective. Cleavage by host proteases essential viral infection. Here, we discovered that contains two previously unidentified Cathepsin L (CTSL) cleavage sites (CS-1 CS-2). Both are highly conserved among all known SARS-CoV-2 variants. Our structural...
Abstract SARS-CoV-2 Omicron sublineages BA.2.12.1, BA.4 and BA.5 exhibit higher transmissibility over BA.2 1 . The new variants’ receptor binding immune evasion capability require immediate investigation. Here, coupled with Spike structural comparisons, we show that BA.2.12.1 BA.4/BA.5 comparable ACE2-binding affinities to BA.2. Importantly, display stronger neutralization than against the plasma from 3-dose vaccination and, most strikingly, post-vaccination BA.1 infections. To delineate...
Abstract The emergence of SARS-CoV-2 variants and potentially other highly pathogenic sarbecoviruses in the future highlights need for pan-sarbecovirus vaccines. Here, we discovered a new STING agonist, CF501, found that CF501-adjuvanted RBD-Fc vaccine (CF501/RBD-Fc) elicited significantly stronger neutralizing antibody (nAb) T cell responses than Alum- cGAMP-adjuvanted mice. Vaccination rabbits rhesus macaques (nonhuman primates, NHPs) with CF501/RBD-Fc exceptionally potent nAb against its...